
Claims

1. Use of a compound represented by the formula (I):



(I)

or a pharmaceutically acceptable salt thereof, for the manufacture of a therapeutic and/or prophylactic agent for frontal lobe dysfunction.

2. The use according to claim 1, wherein the frontal lobe dysfunction is cognitive impairment.

3. The use according to claim 2, wherein the cognitive impairment is cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy or frontotemporal dementia.

4. The use according to claim 2, wherein the cognitive impairment is cognitive impairment in Parkinson's disease.


5. The use according to claim 4, wherein the cognitive impairment in Parkinson's disease is executive dysfunction, memory disorder, impairment in visual spatial cognition or smell disturbance.

6. The use according to claim 2, wherein the cognitive impairment is cognitive impairment caused by chronic stress.

7. The use according to claim 2, wherein the cognitive impairment is dementia with lewy bodies.

8. The use according to claim 1, wherein the frontal lobe dysfunction is cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex.

9. Use of a compound represented by the formula (I):



(I)

or a pharmaceutically acceptable salt thereof, for the manufacture of a therapeutic and/or prophylactic agent for Lewy body disease.

10. The use according to claim 9, wherein the Lewy body disease is cognitive impairment in Parkinson's disease.

11. The use according to claim 9, wherein the Lewy body disease is diffuse Lewy body disease.

12. The use according to claim 9, wherein the Lewy body disease is dementia with lewy bodies.

13. The use according to claim 9, wherein the Lewy body disease is movement disorder associated with Lewy body disease.